Allschwil, Switzerland April 16, 2025 In a significant development for Idorsia Ltd (SIX: IDIA), the company has announced that it has received crucial court approval concerning its outstanding convertible bond, known as the CB 2025. This hearing, conducted by the higher cantonal composition authority (obere kantonale Nachlassbehrde), focused on the convertible bond with a nominal value of CHF 200 million and a conversion price of CHF 6.00 per Idorsia share, which initially reached maturity on January 17, 2025.

During the proceedings held yesterday, the court sanctioned amendments to the bond terms that were decided upon during a bondholder meeting on February 25, 2025. This approval is pivotal, as it allows for the extension of the bond's maturity date until September 17, 2025, provided that no appeal is lodged against the court's decision. The new terms will take effect within a 30-day period following the official publication of the court's written statement explaining its decision. For stakeholders seeking additional information, all relevant details regarding the bondholder meeting are accessible at www.idorsia.com/CB2025.

This extension of the CB 2025 maturity is not merely a stopgap measure; it represents the initial phase in a comprehensive restructuring strategy that Idorsia announced in a press release on February 26, 2025. This broader strategy aims to create a conducive environment for implementing necessary structural changes within the company, allowing it the time needed to execute these plans effectively.

In the upcoming weeks, Idorsia is expected to provide further updates regarding the holistic restructuring process. This will include critical information on the timing related to a new money facility subscription process, along with details about an exchange offer that is in the works.

About Idorsia

Idorsia Ltd is on an ambitious journey to redefine medical standards. Located in an advantageous hub near Basel, Switzerland, which is recognized as a significant center for biotechnological advancements, the company is driven by a profound passion for scientific exploration. Idorsia aims to challenge existing medical paradigms by addressing the most pressing questions in healthcare. Its mission is to discover, develop, and commercialize transformative medicines, leveraging both in-house capabilities and strategic partnerships.

With a diverse and highly skilled team, Idorsia boasts expertise spanning all facets of drug development, from initial research to patient care. One of its standout products, QUVIVIQ (daridorexant), represents a novel approach to treating insomnia, a growing public health concern. The company also maintains a robust pipeline of promising in-house developments and collaborates with partners to maximize the potential of its expanding portfolio.

Investors can find more information on Idorsias progress and initiatives by contacting the Investor & Media Relations department at Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, or by calling +41 58 844 10 10. They may also reach out via email at investor.relations@idorsia.com or media.relations@idorsia.com, or visit their website at www.idorsia.com.

It is essential to note that this announcement contains certain forward-looking statements, which can be identified by terms such as "estimates," "believes," "expects," and other similar expressions. These statements reflect the company's current views regarding future events and are subject to inherent risks and uncertainties that could lead to actual results differing materially from those anticipated.

For further details, stakeholders are encouraged to review the full statements and consider the broader implications of this approval on Idorsia's strategic trajectory.